Holen Sie sich die Stockscreener-App
168.57
0.44%
-0.74
Handel nachbörslich:
166.00
-2.57
-1.52%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$169.31
Offen:
$169.03
24-Stunden-Volumen:
1.56M
Relative Volume:
0.81
Marktkapitalisierung:
$24.73B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.13
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
-9.37%
1M Leistung:
-4.08%
6M Leistung:
+32.21%
1J Leistung:
+19.55%
1-Tages-Spanne:
$166.79
$169.79
1-Wochen-Bereich:
$165.58
$190.20
52-Wochen-Spanne:
$110.03
$190.20
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
168.57 | 24.84B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,032.97 | 960.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
219.57 | 526.55B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.75 | 392.16B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.97 | 275.53B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
143.15 | 280.45B | 54.45B | 14.42B | 17.15B | 7.333 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Acute Ischemic Stroke Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Genentech, NoNO, Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell - Barchart.com
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB) - Seeking Alpha
Europe clears Biogen’s high-dose Spinraza regimen - The Pharma Letter
Biogen Inc.: Can a Neuroscience Pioneer Still Out-Innovate the Biotech Pack? - AD HOC NEWS
Biogen Inc. stock underperforms Wednesday when compared to competitors - MSN
Biogen (NASDAQ:BIIB) Shares Down 5.9%Time to Sell? - MarketBeat
Biogen falls after flagging $222 million charge to profit in Q4 - TradingView — Track All Markets
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence - BioSpace
What to Expect From Biogen's Next Quarterly Earnings Report - Yahoo Finance
Biogen Sees $1.26 Per Share Impact From IPR&D, Milestone Expenses In Q4 - Nasdaq
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly - Investing.com
Biogen sees Q4 IPR&D impacts on EPS by ~$1.26/share - MSN
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways - GlobeNewswire Inc.
Biogen Expects Q4 Expense of $222 Million - marketscreener.com
Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB) - The Globe and Mail
Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact f - GuruFocus
BiogenCharge to impact Q4 net income by $1.26 per shareSEC filing - marketscreener.com
Biogen’s Q4 preliminary EPS comes in below consensus By Investing.com - Investing.com Canada
Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug - Bloomberg.com
The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - simplywall.st
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery - Yahoo Finance
Biogen stock outlook remains positive as RBC reiterates Outperform rating By Investing.com - Investing.com UK
Biogen on the hunt for acquisition after $1B in cuts, 15% workforce reduction - The Business Journals
GRIMES & Co WEALTH MANAGEMENT LLC Sells 5,727 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy - Nasdaq
Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference - Yahoo Finance
United States Biosimilars and Biologics Market to hit US$ 532.13 - openPR.com
Biogen (BIIB) Gains European Approval for High Dose SPINRAZA Reg - GuruFocus
Biogen Advances Presymptomatic SMA Strategy With New Salanersen Trial - TipRanks
Biogen says co received European Commission approval for high dose regimen of Spinraza - marketscreener.com
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - Biogen
Biogen Receives European Commission Approval for High Dose - GlobeNewswire
SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs - Reuters
Biogen Inc. (BIIB) Stock Analysis: Navigating a 1.82% Potential Upside Amid Strategic Developments - DirectorsTalk Interviews
Spinal Muscular Atrophy Market Set for Rapid Growth, Demand, - openPR.com
Biogen (BIIB) Advances with Zorevunersen Development Program - GuruFocus
Trial of new Dravet syndrome drug moves faster, with key results in 2027 - Stock Titan
Cerity Partners LLC Increases Position in Biogen Inc. $BIIB - MarketBeat
3 Reasons to Sell BIIB and 1 Stock to Buy Instead - The Globe and Mail
Here's What Analysts Think About Biogen Inc. (BIIB) - Finviz
Here’s What Analysts Think About Biogen Inc. (BIIB) - Insider Monkey
EBIT per share of Biogen Inc. – DUS:IDP - TradingView — Track All Markets
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail - MSN
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy - TipRanks
Bernstein Adjusts Price Target on Biogen to $197 From $157, Maintains Market Perform Rating - marketscreener.com
Biogen’s Alzheimer’s Treatment Gains Crucial Momentum in Chinese Market - AD HOC NEWS
Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - simplywall.st
Responsive Playbooks and the BIIB Inflection - Stock Traders Daily
How Biogen Inc. stock performs in high volatility marketsJobs Report & Weekly Watchlist of Top Performers - ulpravda.ru
Will Biogen Inc. stock continue dividend increasesJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.70%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):